This is a post approval study of Coaptite® in the treatment of female urinary incontinence.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
459
Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
Unnamed facility
Wetumpka, Alabama, United States
Unnamed facility
Surprise, Arizona, United States
Unnamed facility
Encinitas, California, United States
Incontinence Status as Assessed by Stamey Grade Score
The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).
Time frame: Baseline and Months 6, 12, 18, 24, 30, and 36
Number of Participants With One Point Improvement in Stamey Grade Scores up to Month 12
The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).
Time frame: Baseline up to Month 12
Number of Participants Who Had at Least One Point Improvement in Stamey Grade Scores Compared to Baseline
The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Oceanside, California, United States
Unnamed facility
Orange, California, United States
Unnamed facility
Templeton, California, United States
Unnamed facility
Celebration, Florida, United States
Unnamed facility
Orlando, Florida, United States
Unnamed facility
St. Petersburg, Florida, United States
...and 10 more locations
Time frame: Months 6, 12, 18, 24, 30, and 36
Number of Participants With Change From Baseline in Stamey Grade Scores Over Time
The Stamey grade classifies the severity stress incontinence and was calculated from the 4-day voiding diary using the four possible grades from 0-3. Grade 0: controlled urination, Grade 1: accidents with vigorous activity, for example, lifting weights, coughing, and sneezing, Grade 2: accidents with minimal activity, for example, walking and standing up, and Grade 3: accidents regardless of activity or position and that cannot be attributed to a specific activity. Higher the Stamey grade, the most severe leakage level was estimated. An average of 4 days for the final grade was recorded and rounded up, if necessary (for example, 2.5 was equal to Grade 3).
Time frame: Baseline up to Months 6 and 12
Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
Time frame: Baseline up to Month 36
Number of Participants Who Received Each of the Six Coaptite Injections
Coaptite injection were given to any participant during the 36 months of evaluation.
Time frame: Baseline up to Month 36
Time to Coaptite Retreatment
Time to additional coaptite treatment or any other alternative treatment for stress urinary incontinence was recorded to assess the durability of effect.
Time frame: Baseline up to Month 36
Number of Participants With Alternative Treatments for Incontinence
Number of participants with alternative treatment such as kegel exercises, sling, sling/cystocele repair, surgery, permanent abdominal tube, intravesical botox, sling/graft, sling removal, estradiol vaginal cream, bladder neck suspension, tension free vaginal tape, biofeedback, polydimethylsiloxane injections, solifenacin orally, bladder specific control physical therapy, for stress urinary incontinence were assessed.
Time frame: Baseline up to Month 6 and Months 6 to 12, 12 to 18, 18 to 24, 24 to 30, 30 to 36
Number of Participants With Urge Incontinence Medication (UIM) Status
The use of urge incontinence medications was collected pre-treatment and post-treatment.
Time frame: Baseline up to Month 36
Incontinence Quality of Life (iQoL) Scores
The iQoL measured the effect of urinary incontinence on QoL. It was divided into 3 subscales: 1 (avoidance and limiting behaviour); 2 (psychosocial impact), and 3 (social embarrassment). The iQOL was comprised of 22 items, each with the response scale from 1 (extremely) to 5 (not at all). A mean score for each subscale was calculated (averaging the scores for the items in each subscale) as well as a total score for all 22 items (sum of all subscale scores). The scores were then transformed to a scale score ranging from 0 to 100 points, where higher scores indicated less impact of incontinence on QoL.
Time frame: Baseline and Months 6, 12, 18, 24, 30, and 36
Volume of Coaptite Injected Per Treatment
Time frame: Baseline, Baseline to Month 6 and Months 6 to 12, 12 to 18, 18 to 24, 24 to 30, 30 to 36
Mean Number of Sites Injected by Coaptite
Time frame: Baseline, Baseline to Month 6 and Months 6 to 12, 12 to 18, 18 to 24, 24 to 30, 30 to 36